Illumina, Inc., introduced the world’s largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Billion Cell Atlas is being developed under an alliance framework with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), AstraZeneca, and Eli Lilly and Company as founding participants. MSD will leverage the Atlas to accelerate precision medicine approaches across their drug discovery pipelines.
